Masatomo Miura

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

Naoto Takahashi, Masatomo Miura, Stuart A. Scott et al. · Journal of Human Genetics · 2010 · 162 citations · Full text

Hematological Malignancy, Oncology, Medicine +9

Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

Masatomo Miura, Shigeru Satoh, Kazuyuki Inoue et al. · European Journal of Clinical Pharmacology · 2007 · 149 citations

Urology, Transplantation, Kidney Transplant +12

New Type of Febrifugine Analogues, Bearing a Quinolizidine Moiety, Show Potent Antimalarial Activity against <i>Plasmodium</i> Malaria Parasite

Yoshiaki Takaya, Hidehisa Tasaka, Tomoyuki Chiba et al. · Journal of Medicinal Chemistry · 1999 · 139 citations

New Type, Antiparasitic Agent, Malaria +17

Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure

Susan E. Tett, Franck Saint‐Marcoux, Christine E. Staatz et al. · Transplantation Reviews · 2010 · 136 citations

Drug Safety, Pharmacokinetic Modeling, Medicine +5

Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model

Masatomo Miura · International Journal of Oncology · 2009 · 119 citations · Full text